This guide compares the Wegovy pill and Mysimba at the level of how they work and what is available, with Mysimba licensed and available today and the Wegovy pill not yet UK-licensed. It does not compare their efficacy as UK fact, because the pill has no UK results picture yet. It is grounded in the UK-licensed product information and is general information.
Two different oral medicines
The Wegovy pill and Mysimba are both oral, but they are different medicines with different active ingredients and mechanisms 15. The pill is oral semaglutide; Mysimba is a combination of bupropion and naltrexone15.
So unlike comparing two GLP-1 products, this is a comparison between a GLP-1 medicine and a medicine that works through different pathways 15. They are not variations on the same approach 5.
Understanding that difference in mechanism is the foundation for the comparison, because it shapes side effects, cautions and who each might suit 51. The rest of this guide builds on it 5.
How the Wegovy pill is meant to work
The Wegovy pill is oral semaglutide, designed to act on appetite regulation via the GLP-1 system, reducing energy intake and hunger, the same mechanism as the Wegovy injection 1. It works on the appetite side 1.
It is not yet licensed in the UK, so this guide makes no efficacy, dose or safety claims for it as UK fact 14. Its UK details would come from its licence once approved 4.
For the comparison, the key point is that the pill is a GLP-1 appetite medicine, which is a different mechanism from Mysimba's 15. That contrast is genuine even while the pill remains under review 1.
How Mysimba works
Mysimba combines bupropion and naltrexone, two active substances that act on pathways involved in appetite and the control of eating, which is a different mechanism from a GLP-1 medicine 5. It is taken as tablets with a gradual dose build-up 5.
Because of its ingredients, Mysimba has its own specific cautions, contraindications and side-effect profile, including considerations around mood and seizure risk that are set out in its product information and assessed before it is prescribed 5. It is not suitable for everyone 5.
Mysimba is licensed and available in the UK now, for weight management in eligible people alongside diet and activity 5. It can be discussed with a clinician as a current option following a proper assessment 52.
Want to know when the Wegovy pill (oral semaglutide) becomes available in the UK? It is not yet licensed here, but you can join the waitlist to be notified, and explore the licensed options with a Cloud Pharmacy clinician in the meantime.
Availability: one is here now, one is not
The decisive practical difference is availability 54. Mysimba is licensed and available in the UK today; the Wegovy pill is not yet UK-licensed54. So for anyone choosing now, Mysimba is a real oral option while the pill is not 5.
That makes the comparison partly forward-looking on the pill's side 4. A present-day decision really means weighing Mysimba against the other licensed options that exist now 51.
Any 'Wegovy pill' offered before UK licensing should be treated as a warning sign, given the NHS warning about fake weight-loss medicines 2. Genuine availability would come through registered pharmacies once it is licensed 24.
Why we don't compare their effectiveness
This guide does not compare the effectiveness of the Wegovy pill and Mysimba as UK fact 4. Mysimba has a UK results picture from its licence; the pill does not yet, so a head-to-head efficacy claim would go beyond UK sources 54.
What can be said is that they work through different mechanisms, so they suit different people, and suitability depends on your health, other medicines and the specific cautions each carries, not on a single effectiveness number 51. A clinician weighs these 2.
Once the Wegovy pill has a UK licence and results picture, a more direct comparison would be possible 4. Until then, this guide compares mechanism and availability, which is the honest basis 54.
Which might suit you, and what to do now
Choosing between oral options is a clinical decision based on how each works, the cautions and contraindications, your health and other medicines, and your eligibility, made with a prescriber 51. Mysimba in particular has specific suitability considerations that an assessment would check 5.
For now, Mysimba is an available oral option to discuss with a clinician, and the other licensed weight-management medicines are available too 51. A proper assessment can establish what suits you today 2.
If it is specifically the Wegovy pill you want, you can join the waitlist to be notified when it is available, while considering the licensed options in the meantime 42. Our guide on choosing a weight-loss treatment sets the licensed options side by side 1.
Suitability and safety considerations
A key part of comparing these medicines is that suitability differs51. Mysimba carries specific cautions and contraindications because of its ingredients, including considerations around mood, mental health and seizure risk, which are set out in its product information and checked before it is prescribed 5.
That means Mysimba is not suitable for everyone, and a proper assessment is needed to establish whether it is appropriate for you, taking account of your history and other medicines 52. It is a good example of why weight-loss medicines are prescription-only rather than something to choose unaided 5.
An oral semaglutide would have its own suitability profile, with its specific cautions and contraindications defined by the pill's UK product information once licensed 14. So comparing suitability fully will only be possible once the pill is licensed here 4.
If you have mental-health considerations, are taking other medicines, or have any health conditions, those are exactly the things a clinician would weigh in deciding which option, if any, suits you 52. This is not a decision to make on the basis of a comparison page alone 51.
Different mechanisms suit different people
Because the Wegovy pill and Mysimba work through different mechanisms, they are best seen as different options for different people rather than direct rivals 15. One acts on appetite via GLP-1; the other works through the bupropion and naltrexone pathways 15.
That means the right choice depends on the individual, their health, their tolerance, the cautions each medicine carries, and their preferences, rather than on a single ranking 51. A medicine that suits one person may be unsuitable for another, particularly given Mysimba's specific contraindications 5.
It also means a head-to-head effectiveness comparison would miss much of what matters, especially as the Wegovy pill has no UK results picture yet 45. Fit and safety weigh at least as heavily as any effectiveness figure 51.
So the sensible approach is to discuss your circumstances with a clinician, consider Mysimba and the other licensed options that are available now, and join the Wegovy pill waitlist if the pill is specifically what you want for the future 542.
One practical point worth noting is that Mysimba is genuinely available today, so for someone who is suitable for it, it is something they can act on now rather than wait for 5. That availability matters when weighing it against a pill that is not yet licensed here 54.
As with any of these comparisons, the right question is less 'which is best in the abstract' and more 'which suits me, and what can I safely start now', which a clinician is best placed to answer with your full history in front of them 512.
Mysimba's specific cautions make that individual assessment especially important here 5. Because its contraindications rule it out for some people, the comparison with an oral semaglutide is not just about preference but about which medicine is safe for you in the first place, which only a proper assessment can establish 52.
So when the Wegovy pill is eventually licensed, the most useful way to compare it with Mysimba will be through a clinician who can weigh the different mechanisms, the cautions each carries, and your own health, rather than through a headline ranking 514. Until then, Mysimba and the other licensed options are what is actually available to consider 52. Joining the Wegovy pill waitlist keeps you informed about the future option without relying on an unlicensed source in the meantime, while a clinician helps you with what is available now 42.
It is also worth being realistic that no oral medicine replaces the diet and activity changes that underpin weight management 51. Mysimba is used alongside a reduced-calorie diet and increased activity, and semaglutide likewise, so whichever you consider, the lifestyle side stays part of the plan rather than something the medicine does away with 51.
Keeping that in mind helps set realistic expectations and avoids treating any pill as a standalone fix 51. The medicine, whichever it is, works best as one part of a wider, supported approach that a clinician can help you put together 52. That perspective applies just as much to the Wegovy pill in future as it does to the options available now 41.
Frequently asked questions
How is the Wegovy pill different from Mysimba?
They are different medicines: the Wegovy pill is oral semaglutide acting on appetite via GLP-1, while Mysimba combines bupropion and naltrexone, which act on different pathways 15. Mysimba is available now; the Wegovy pill is not yet UK-licensed 54.Is Mysimba available now?
Yes, Mysimba is licensed and available in the UK for weight management in eligible people, and can be discussed with a clinician after a proper assessment 5. The Wegovy pill is not yet UK-licensed 4.Which works better, Mysimba or the Wegovy pill?
This guide does not compare their efficacy as UK fact, because the pill has no UK results picture yet 54. They work differently and suit different people; a clinician can weigh the options for you 52.Is Mysimba suitable for everyone?
No. Mysimba has specific cautions and contraindications, including considerations around mood and seizure risk, set out in its product information and assessed before prescribing 5. A proper assessment checks suitability 52.Can I get the Wegovy pill instead of Mysimba now?
No. Mysimba is available now, but the Wegovy pill is not yet UK-licensed 54. Any 'Wegovy pill' offered now is a warning sign, given the NHS warning about fake weight-loss medicines 2.What should I do if I want the Wegovy pill?
Join the waitlist to be notified when it is available, and consider the licensed options, including Mysimba, with a clinician in the meantime 42. A proper assessment can establish what suits you now 2.Your next step
The Wegovy pill and Mysimba are different oral medicines that work in different ways: the pill is oral semaglutide acting on appetite via GLP-1, while Mysimba combines bupropion and naltrexone, which act on different pathways and carry their own specific cautions, including considerations around mood and seizure risk. That difference in mechanism shapes side effects and who each might suit.
The decisive practical point is that Mysimba is licensed and available in the UK now, while the Wegovy pill is not yet UK-licensed, so a present-day choice is really between Mysimba and the other licensed options. This guide does not compare their efficacy as UK fact, because the pill has no UK results picture yet. Choosing an oral option is a clinical decision made with a prescriber after a proper assessment; if you specifically want the Wegovy pill, join the waitlist to be notified when it is available and consider the licensed options in the meantime.
Disclaimer
This guide is for general information only and does not constitute medical advice, diagnosis or treatment. The information here describes general clinical context based on UK regulatory sources cited above; it is not a recommendation for any specific medicine or treatment, which can only be made by a prescriber following individual assessment.
If you are considering treatment, speak to your GP or pharmacist, or arrange a consultation with a Cloud Pharmacy clinician. Prescription-only medicines are issued only after clinical assessment and where appropriate.
If you experience side effects from any medicine, you can report them through the Yellow Card scheme at yellowcard.mhra.gov.uk.
References
- Wegovy SmPC 4.1/5.1 (semaglutide; GLP-1 appetite-regulation mechanism; licensed weight-management INJECTION; used to describe the Wegovy pill's molecule, NOT to assert the pill's efficacy)
- Semaglutide (registered pharmacy; some websites sell fake weight-loss medicines; assessment; general framing)
- General UK framing; Wegovy pill not UK-licensed (June 2026); no pill efficacy/dose asserted; waitlist route
- Mysimba SmPC 4.1/4.2/4.3/4.4/4.8/5.1 (bupropion/naltrexone combination; appetite/control-of-eating pathways; gradual dose escalation; cautions/contraindications incl. mood and seizure risk; licensed and available for weight management)
